fda warning letters compounded semaglutide october 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Warns on Certain Forms
Description
A treatment with DPP-4 inhibitors should be stopped when GLP-1 receptor agonists are used
Medicare does not currently cover weight-loss drugs as a standard benefit
We teach them to preserve relationships
detection of GLP-1R mRNA in situ hybridization
They often mean more side effects without additional metabolic benefit
